Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2013 (2013), Article ID 406165, 6 pages
Research Article

Does the RIFLE Classification Improve Prognostic Value of the APACHE II Score in Critically Ill Patients?

Department of Postgraduate Medicine and Human Health, Bahia School of Medicine and Public Health (EBMSP), Avenida D. João VI 275, PAV.II, 2° Andar, Sala 07, Brotas, 40.290-000 Salvador, BA, Brazil

Received 5 May 2013; Accepted 17 July 2013

Academic Editor: Jaime Uribarri

Copyright © 2013 Kátia M. Wahrhaftig et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. The RIFLE classification defines three severity criteria for acute kidney injury (AKI): risk, injury, and failure. It was associated with mortality according to the gradation of AKI severity. However, it is not known if the APACHE II score, associated with the RIFLE classification, results in greater discriminatory power in relation to mortality in critical patients. Objective. To analyze whether the RIFLE classification adds value to the performance of APACHE II in predicting mortality in critically ill patients. Methods. An observational prospective cohort of 200 patients admitted to the ICU from July 2010 to July 2011. Results. The age of the sample was 66 (±16.7) years, 53.3% female. ICU mortality was 23.5%. The severity of AKI presented higher risk of death: class risk (RR = 1.89 CI:0.97–3.38, ), grade injury (RR = 3.7 CI:1.71–8.08, ), and class failure (RR = 4.79 CI:2.10–10.6, ). The APACHE II had C-statistics of 0.75, 95% (CI:0.68–0.80, ) and 0.80 (95% CI:0.74 to 0.86, ) after being incorporated into the RIFLE classification in relation to prediction of death. In the comparison between AUROCs, . Conclusion. The severity of AKI, defined by the RIFLE classification, was a risk marker for mortality in critically ill patients, and improved the performance of APACHE II in predicting the mortality in this population.